Monte Rosa强调更新后的1/2期数据显示，在重度预治疗的mCRPC中，RECIST总体疾病控制率和肿瘤减少率为67%

2026-02-24 20:19

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions
Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions
Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs
Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant patients in Q3 2026